Skip to main content
Clinical Trials/NCT03732612
NCT03732612
Recruiting
Not Applicable

The Role of Inflammation in Vascular Disease (Inflammationens Roll i kärlsjukdom)

Göteborg University1 site in 1 country170 target enrollmentSeptember 2, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vascular Diseases
Sponsor
Göteborg University
Enrollment
170
Locations
1
Primary Endpoint
Inflammatory status
Status
Recruiting
Last Updated
12 months ago

Overview

Brief Summary

Increasing evidence suggests that systemic low-grade inflammation may be a driving force of cardiometabolic complications, such as vascular dysfunction, atherosclerosis and ischemic heart disease. Thus, we will investigate the role of inflammation in cardiovascular disease.

Detailed Description

Vascular reconstruction surgeries usually require a small piece of the vessel wall to be excised. The excised vessel is generally discarded as medical waste: however, for patients participating in the study, the excised tissue will be placed in saline and collected for research use. Tissue collected from individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue will be cultured ex vivo in the presence or absence of therapeutic agents, to determine if these attenuate the inflammation associated with the atherosclerotic phenotype. Furthermore, the protocol will also be carried out using vascular tissue from control patients, which have undergone vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc).

Registry
clinicaltrials.gov
Start Date
September 2, 2019
End Date
February 1, 2027
Last Updated
12 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Göteborg University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient is planned to undergo vascular surgery.
  • Signed informed consent has been obtained from the patient.

Exclusion Criteria

  • Patient has difficulty to understand information.
  • Patients under 18 years of age.
  • Patients participating in any drug-related study.

Outcomes

Primary Outcomes

Inflammatory status

Time Frame: 2019-2024

The inflammatory status will be studied in patients with atherosclerotic disease.

Study Sites (1)

Loading locations...

Similar Trials